Evidence map›Paper›PMID 40343572›Full record

ArticleCancer immunology, immunotherapy : CII2025

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W Myint and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Camillo Porta *Interdisciplinary Department of Medicine, University of Bari "A. Moro", Bari, Italy. camillo.porta@gmail.com.
Francesco Massari *Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Tarek TahaRoyal Marsden NHS Foundation Trust, London, UK.
Enrique GrandeDepartment of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
Maria T BourlonDepartment of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico - Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Umberto BassoOncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Javier Molina-CerrilloDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
Teresa Alonso-GordoaDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
Zin W MyintDivision of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Giuseppe FornariniIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Thomas ButtnerDepartment of Urology, University Hospital Bonn (UKB), Bonn, Germany.
Se Hoon ParkDepartment of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea.
Yüksel ÜrünDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Ugo De GiorgiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Renate PichlerDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Pasquale RescignoCentre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
Tomas BuchlerDepartment of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Hana StudentovaDepartment of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Bohuslav MelicharDepartment of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Jawaher AnsariMedical Oncology, Tawam Hospital, Al Ain, UAE.
Veronica MollicaMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Jakub KucharzDepartment of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland.
Mimma RizzoDivision of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazzale G. Cesare 11, 70124, Bari, Italy.
Alessandro RizzoIRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.
Ray Manneh KoppClinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Fernando Sabino Marques MonteiroLatin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.
Andrey SoaresLatin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Matteo SantoniMedical Oncology Unit, Macerata Hospital, Macerata, Italy.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA177558
6 · The paper itself

Abstract

backgroundPembrolizumab plus lenvatinib is a treatment option for metastatic Renal Cell Carcinoma (mRCC). In the ARON-1 study we investigated we the real-world experiences gained from the use of this combination for mRCC.

methodsWe retrospectively investigated real-world clinical outcomes of mRCC patients receiving pembrolizumab plus lenvatinib within the ARON-1 study. Overall survival (OS) was calculated from the start of pembrolizumab plus lenvatinib to death for any cause. Progression-Free Survival (PFS) was defined as the time from the start of pembrolizumab to progression or death from any cause. Duration of response (DoR) was defined as the time from the start of pembrolizumab to disease progression or death, whichever occurred first, in patients who achieved complete remission (CR) or partial response (PR). Overall Response Rate (ORR) was defined as the proportion of patients who achieve a CR or PR per RECIST criteria. Adverse events were retrospectively collected from electronic and paper charts and categorized by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

resultsOverall, we included 202 mRCC patients treated with pembrolizumab plus lenvatinib. The median follow-up time was 15.1 months. The median OS was not reached (NR), with a median PFS of 25.6 months and an Overall Response Rate (ORR) of 59%. The median Duration of Response (DoR) was 26.2 months. G3-G4 adverse events (AEs) were observed in 92 patients (46%), with hypertension being the most common AE (13%).

conclusionsPembrolizumab plus lenvatinib is an effective and tolerable treatment for mRCC also in the real-world setting.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsQuinolinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesAntibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolinesARON- 1Immune-combinationsLenvatinibPembrolizumabReal-world dataRenal cell carcinomaSurvival

Identifiers

PMID40343572
PMCPMC12064502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.